{"id":"NCT01250379","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)","officialTitle":"A Phase III Randomized Study Evaluating the Efficacy and Safety of Continued and Re-induced Bevacizumab in Combination With Chemotherapy for Patients With Locally Recurrent or Metastatic Breast Cancer After First-line Chemotherapy and Bevacizumab Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-02","primaryCompletion":"2013-12","completion":"2015-03","firstPosted":"2010-11-30","resultsPosted":"2015-06-30","lastUpdate":"2016-02-11"},"enrollment":494,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"bevacizumab [Avastin]","otherNames":[]},{"type":"DRUG","name":"Chemotherapy","otherNames":[]}],"arms":[{"label":"1","type":"ACTIVE_COMPARATOR"},{"label":"2","type":"EXPERIMENTAL"}],"summary":"This randomized, open-label, parallel-group study will assess the efficacy and s afety of Avastin (bevacizumab) in combination with chemotherapy versus chemother apy alone as second- and third-line therapy in patients with locally recurrent o r metastatic breast cancer progressing after first-line therapy with Avastin and chemotherapy. Patients will be randomized to receive either Avastin (15 mg/kg e very 3 weeks or 10 mg/kg every 2 weeks intravenously) plus standard chemotherapy or chemotherapy alone. Anticipated time on study treatment is until third-line disease progression or unacceptable toxicity occurs.","primaryOutcome":{"measure":"Percentage of Participants With Second-Line Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)","timeFrame":"Baseline (less than or equal to [â‰¤] 28 days after randomization), every 8-9 weeks thereafter according to the standard of care of the treatment site until approximately 3 years","effectByArm":[{"arm":"CT Arm","deltaMin":88.7,"sd":null},{"arm":"CT+BV Arm","deltaMin":93.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":132,"countries":["Argentina","Austria","Brazil","Croatia","France","Germany","Greece","Hungary","Israel","Italy","Slovakia","Spain","Switzerland"]},"refs":{"pmids":["27502725","25273342"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":55,"n":238},"commonTop":["Proteinuria","Hypertension","Palmar-plantar erythrodysaesthesia syndrome","Neutropenia","Fatigue"]}}